TABLE 6.
Effects of grlA, grlB, and gyrA mutations on the activities of selected quinolones
| Strain | Genotype | MIC (μg/ml) of:
|
||||||
|---|---|---|---|---|---|---|---|---|
| Ciprofloxacin | Norfloxacin | DU-6859a | Sparfloxacin | Nalidixic acid | Oxolinic acid | Novobiocin | ||
| RN4220 | 0.5 | 1.0 | 0.0312 | 0.12 | 64.0 | 2.0 | 0.16 | |
| BF2 | nov (gyrB142) | 0.5 | 1.0 | NDa | ND | 64.0 | 2.0 | 40.0 |
| EN5 | nov (gyrB142) gyrA | 0.5 | 1.0 | 0.0625 | 0.12 | 256.0 | 4.0 | 40.0 |
| EN22 | grlB543 | 2 | 16.0 | 0.0625 | 0.12 | 64.0 | 4.0 | 0.08 |
| EN20 | grlA542 | 2 | 16.0 | 0.0625 | 0.12 | 64.0 | 4.0 | 0.16 |
| EN14 | nov (gyrB142) grlB543 gyrA | 4 | 8.0 | 0.125 | 2.0 | 128.0 | 8.0 | 10.0 |
| EN8 | nov (gyrB142) grlA542 gyrA | 32 | 64.0 | 0.5 | 16.0 | 256.0 | 128.0 | 40.0 |
a
ND, not determined.